Table 2.
Demographics and baseline disease characteristics of patients in MG0002 study [21]
| Total (n = 43) | |
|---|---|
| Age (in years), mean (SD) | 51.9 (15.1) |
| Gender, female—n (%) | 27 (62.8%) |
| Country—n (%) | |
| Canada | 11 (25.6%) |
| Belgium | 10 (23.3%) |
| United States of America | 9 (20.9%) |
| Denmark | 7 (16.3%) |
| Germany | 3 (7.0%) |
| Czech Republic | 2 (4.7%) |
| Spain | 1 (2.3%) |
| Auto-antibody class—n (%) | |
| AChR | 40 (93.0%) |
| MuSK | 1 (2.3%) |
| QMG score at baseline, mean (SD) | 15.6 (3.9) |
| MGC score at baseline, mean (SD) | 15.6 (6.2) |
| MG-ADL score at baseline, mean (SD) | 7.1 (3.1) |
| MG Symptoms PRO scores at baseline, mean (SD) | |
| Bulbar Muscle Weakness | 24.0 (17.7) |
| Muscle Weakness Fatigability | 43.8 (22.4) |
| Physical Fatigue | 49.2 (21.7) |
| Ocular Muscle Weakness | 31.5 (20.7) |
| Respiratory Muscle Weakness | 38.0 (25.8) |
| MGFA classification—n (%) | |
| Class I | 0 (0.0%) |
| Class IIa | 7 (16.3%) |
| Class IIb | 12 (27.9%) |
| Class IIIa | 15 (34.9%) |
| Class IIIb | 6 (14.0%) |
| Class IVa | 2 (4.7%) |
| Class IVb | 1 (2.3%) |